Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study.
Kaplan MA, Ozaydin S, Yerlikaya H, Karaagac M, Gumus M, Cil T, Yalcintas Arslan Ü, Ozdemir N, Sakin A, Bilici M, Koca D, Uysal M, Dane F, Sever ÖN, Seker MM, Oruc Seker Z, Can MF, Geredeli C, Aksoy A, Pilanci KN, Ozturk Topcu T, Isikdogan A. Kaplan MA, et al. Among authors: sever on. Oncol Res Treat. 2019;42(10):516-522. doi: 10.1159/000502120. Epub 2019 Aug 22. Oncol Res Treat. 2019. PMID: 31437835
Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases): multicenter experiences.
Anatolian Medical Oncology Society Group; Ustaalioglu BB, Gumus M, Unal A, Cayir K, Sever O, Bilici A, Elkiran ET, Karaca H, Benekli M, Karaoglu A, Seker M. Anatolian Medical Oncology Society Group, et al. Int J Gynecol Cancer. 2010 Jul;20(5):698-703. doi: 10.1111/igc.0b013e3181daaf3e. Int J Gynecol Cancer. 2010. PMID: 20973261 Review.
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. Yekedüz E, et al. Among authors: sever on. J Cancer Res Clin Oncol. 2022 Dec;148(12):3537-3546. doi: 10.1007/s00432-022-04055-5. Epub 2022 May 26. J Cancer Res Clin Oncol. 2022. PMID: 35616728
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Yekedüz E, et al. Among authors: sever on. Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2. Future Oncol. 2021. PMID: 34726480
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.
Erol C, Yekedüz E, Tural D, Karakaya S, Şentürk Öztaş N, Uçar G, Kılıçkap S, Ertürk İ, Sever ÖN, Arslan Ç, Küçükarda A, Can O, Balvan Ö, Yazgan SC, Özgüroğlu M, Öksüzoğlu B, Şendur MAN, Ürün Y. Erol C, et al. Among authors: sever on. Urol Int. 2023;107(6):595-601. doi: 10.1159/000528994. Epub 2023 Mar 30. Urol Int. 2023. PMID: 36996793
33 results